Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Chronic Asthma
Phase Not Applicable
Enrollment 1200
Locations 8 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Primary objective \- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment Secondary objective(s) * To study biomarkers variation post-treatment in patients with and without Nasal Polyposis * To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous * To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Antiasthmatic — real-life

Primary Outcomes

  • Correlation between non-invasive T2 biomarkers versus biomarkers in sputum (at date of randomization and after one year of follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-01
Completion: 2026-06-02
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Collaborators: Sanofi
Principal Investigators:
  • Joaquin Sastre (STUDY_DIRECTOR) - Fundacion Jimenez Diaz
Contact Information
Study Contact:
Joaquin S Sastre
34609835363
jsastre@fjd.es
FRANCISCO JAVIER GONZALEZ-BARCALA, MD, PhD
+34607 819 141
fjgbarcala@gmail.com
Hospital Universitario Santiago de Compostela
CARLOS MARTINEZ-RIVERA, MD, PHD
34934651200
carlosmartinezrivera.cmr@gmail.com
Hospital Universitario Germans Trias
Interventions
  • Drug: Antiasthmatic — real-life
Study Locations (8 sites)
Hospital Universitario Santiago de Compostela, Santiago de Compostela, Acoruña 15706 Spain
Hospital Universitario Germans Trias, Badalona, BARCELONA 08916 Spain
Hospital Universitari Vall de Hebron, Barcelona, BARCELONA 08035 Spain
Hospital Clinic, Barcelona, BARCELONA 08036 Spain
Hospital Universitario Sant Pau, Barcelona, BARCELONA 08041 Spain
Hospital Del Ferrol, A Coruña, LA CORUÑA 15405 Spain
Hospital Universitario La Paz, Madrid, Madrid 28046 Spain
Hospital Universitario de Navarra, Pamplona, Navarre 31008 Spain
Eligibility Criteria
Inclusion Criteria: For the general asthma cohort (MEGA): * Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol/salbutamol or positive methacholine test) of several severities attended at participant centres * Already in follow-up in MEGA cohort * To participate in the study * Signed informed consent Inclusion criteria for asthma patients treated with biologics * Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg/day of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 \<80%/FEV1/FVC \<70+ACQ-5 score ≥ 1.5/ ACT \< 19 at inclusion and/or have experience any of the following events on the last year: treatment with systemic steroids/ hospitalization or emergency medical care visit for worsening asthma. * When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE \> 75 and \< 1500 UI * Patients already in follow-up in the cohort of patients treated with biologics * Willing to participate in the study * Sign informed consent Exclusion Criteria: * Exclusion criteria for MEGA COHORT * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders * Patients participating in other clinical trials * Patients without the capacity to understand the aim of the study * Exclusion criteria for asthma patients treated with biologics * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders * Patients participating in other clinical trials * Patients without the capacity to understand the aim of the study
Conditions Anxiety Symptom, Depression Symptom
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This 12-week single-arm clinical trial investigates the effects of Traditional Chinese Medicine (TCM) Daoyin exercise on anxiety and depression symptoms in 20 participants, followed by a 12-week observational follow-up period. The primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA-14) and Hamilton Depression Rating Scale (HAMD-17) scores at 12 weeks. A secondary outcome will assess these scores at 24 weeks to evaluate sustained effects. Additional secondary outcomes include the Depression, Anxiety, and Stress Scale (DASS-21) and Pittsburgh Sleep Quality Index (PSQI) to further assess changes in mood and sleep quality at the same time points. Exploratory analyses will examine inflammatory markers, immune cell subsets, serum metabolomics, and gut microbiota at baseline, 12 weeks, and 24 weeks to identify potential biological correlates. During the follow-up period, participants will record their actual exercise engagement, allowing investigators to explore long-term associations. Findings may provide insights for future mechanistic studies on TCM's role in mental health.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: TCM Daoyin exercise — Participants will receive a 12-week, group-based TCM Daoyin intervention consisting of two 90-minute sessions per week (total: 24 sessions), led by qualified physicians. Each session integrates movement regulation, breath regulation, and mind regulation, aiming to alleviate anxiety and depression symptoms. Each session includes a 10-minute warm-up and a 10-minute cool-down. Compliance and Analysis: Per-protocol analysis will include participants who attend ≥80% of sessions (≥19/24 sessions). Safety analyses will be conducted on all enrolled participants (n=20) following the intention-to-treat (ITT) principle.

Primary Outcomes

  • 14-item Hamilton Anxiety Rating Scale (HAMA-14) (Change from Baseline at 12 weeks)
  • 17-item Hamilton Depression Rating Scale (HAMD-17) (Change from Baseline at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-10
Completion: 2027-09-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai University of Traditional Chinese Medicine
Collaborators: Shanghai Mental Health Center
Principal Investigators:
  • Ying Lu, Master (PRINCIPAL_INVESTIGATOR) - Shanghai Qigong Research Institute
Contact Information
Study Contact:
Ying Lu, Master
021-64394141
luyingtcm@163.com
Yanyan Shang, Master
021-64394141
shqgywk@163.com
Ying Lu, Master
luwing_happy@163.com
Shanghai Qigong Research Institute
Interventions
  • Behavioral: TCM Daoyin exercise — Participants will receive a 12-week, group-based TCM Daoyin intervention consisting of two 90-minute sessions per week (total: 24 sessions), led by qualified physicians. Each session integrates movement regulation, breath regulation, and mind regulation, aiming to alleviate anxiety and depression symptoms. Each session includes a 10-minute warm-up and a 10-minute cool-down. Compliance and Analysis: Per-protocol analysis will include participants who attend ≥80% of sessions (≥19/24 sessions). Safety analyses will be conducted on all enrolled participants (n=20) following the intention-to-treat (ITT) principle.
Study Locations (1 sites)
Shanghai Qigong Research Institute, Shanghai, 200030 China
Eligibility Criteria
Inclusion Criteria: * Primary symptoms of anxiety and depression, with a Hamilton Anxiety Rating Scale (HAMA-14) score between 14 and 29 and a Hamilton Depression Rating Scale (HAMD-17) score between 7 and 14. * No prior use of psychotropic medication, or at least six months since discontinuation. * Aged 18 to 65 years (male or female). * Clear consciousness and normal cognitive function, with the ability to communicate effectively, read, express thoughts, and engage in daily activities independently. * Willing and able to comply with blood and stool sample collection. * Voluntary participation, with signed informed consent provided before enrollment. Exclusion Criteria: * Diagnosed anxiety disorder or depressive disorder based on ICD-10 criteria. * Bipolar disorder, psychotic disorders (e.g., schizophrenia), or organic mental disorders (e.g., Alzheimer's disease). * History of alcohol or substance use disorder within the past year, current psychiatric medication use, or high suicide risk. * Severe or unstable medical conditions, including immune or endocrine disorders or other serious illnesses. * Physical or psychological limitations preventing participation in the TCM Daoyin intervention. * Pregnant or breastfeeding women.
Conditions Depression
Phase NA
Enrollment 288
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

In response to large numbers of senior center clients who suffer untreated depression and the dearth of geriatric mental health providers, the investigators have simplified Behavioral Activation to be delivered by lay volunteers ("Do More, Feel Better"; DMFB). The focus of Behavioral Activation is to guide clients to reengage in daily pleasant and rewarding activities, and reduce depressive symptoms. If the investigators can show that the lay delivery model has positive impact in comparison to MSW-delivered Behavioral Activation, the investigators will have identified an effective intervention that can be used by a large untapped workforce of older adult volunteers across the nation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Volunteer-delivered Behavioral Activation — Behavioral Activation as delivered by trained volunteers
  • Behavioral: Master's level clinician-delivered Behavioral Activation — Behavioral Activation as delivered by trained master's level clinicians

Primary Outcomes

  • Hamilton Rating Scale for Depression (HAM-D) (Change from Baseline HAM-D at 3, 6, 9, 24, and 36 weeks after treatment starts)
  • Behavioral Activation Scale (BADS) (Change from Baseline BADS at 3, 6, 9, 24, and 36 weeks after treatment starts)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-27
Completion: 2025-12-01
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 288 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Institute of Mental Health (NIMH), University of South Florida, Weill Medical College of Cornell University
Principal Investigators:
  • Patrick J Raue, PhD (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Brittany Mosser
206-616-2129
dmfb@uw.edu
Dylan Fisher
206-616-2129
dmfb@uw.edu
Mary Goldsworthy
813-974-3576
domorefeelbetter@usf.edu
Brandon Senior Center
Interventions
  • Behavioral: Volunteer-delivered Behavioral Activation — Behavioral Activation as delivered by trained volunteers
  • Behavioral: Master's level clinician-delivered Behavioral Activation — Behavioral Activation as delivered by trained master's level clinicians
Study Locations (25 sites)
Brandon Senior Center, Brandon, Florida 33510 United States
Gardenville Dining & Activity Center, Gibsonton, Florida 33534 United States
Ruskin Senior Center, Ruskin, Florida 33570 United States
JL Young Apartments (Senior Housing), Tampa, Florida 33604 United States
Oaks at Riverview Senior Center, Tampa, Florida 33604 United States
Jewish Towers Senior Housing, Tampa, Florida 33609 United States
Town 'n Country Senior Center, Tampa, Florida 33615 United States
Progress Village Senior Center, Tampa, Florida 33619 United States
Diana Jones Senior Center, Brooklyn, New York 11206 United States
Edie Windsor SAGE Center, New York, New York 10001 United States
Eligibility Criteria
Client Participants (anticipated enrollment: 288) Inclusion Criteria: Referral to study (stage 1): 1. Age ≥ 60 years. 2. Attends one of 18 participating Seattle, NYC, or Tampa area senior centers. 3. Patient Health Questionnaire (PHQ-9) score of ≥10 via routine screening. Research assessment (stage 2): 1. Clinically-assessed HAM-D\>14 2. Mini-Mental Status Exam (MMSE) ≥ 24 OR modified Telephone Interview for Cognitive Status (mTICS) ≥ 19 3. Off antidepressants or on a stable dose for 12 weeks. 4. Capacity to provide written consent for both research assessment and the BA intervention. Client Participants Exclusion Criteria: 1. Current active suicidal ideation. 2. Presence of psychiatric diagnoses other than unipolar, non-psychotic major depression or generalized anxiety disorder by SCID-V (Structure Clinical Interview for DSM-V). 3. Severe or life-threatening medical illness (e.g., end stage organ failure). 4. Inability to speak English or Spanish Volunteer Participants (anticipated enrollment: 36) Inclusion Criteria 1. Age ≥ 60 years. 2. Attends one of the participating Seattle, NYC, or Tampa-area senior centers. Volunteer Participants Exclusion Criteria 1. Current major depressive disorder, alcohol or substance abuse, or manic, hypomanic, or psychotic symptoms (SCID-V); 2. Mini-Mental Status Exam (MMSE) ≥ 24 OR modified Telephone Interview for Cognitive Status (mTICS) ≥ 19; 3. Inability to speak and read English or Spanish Clinician Participants (anticipated enrollment: 36) Inclusion Criteria 1. Master's degree in social work, counseling, marriage/family, or other clinical mental health degree 2. English or Spanish Speaking 3. Capacity to provide consent for all study procedures 4. Willing to audio record study sessions for supervision and evaluation Clinician Participants Exclusion Criteria 1. Non-English or Non-Spanish speaking 2. Does not hold a Master's degree in social work, counseling, marriage/family, or other clinical mental health degree 3. Unable to provide consent 4. Unwilling to audio record study sessions for supervision and evaluation
Conditions Laughter Yoga
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to observe the effects of laughter yoga on psychological well-being and depressive symptoms in older adults.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Lughter yoga — The study divided the intervention and control groups. Participants in the intervention group will be given laughter yoga. Data collection tools will be administered as pre-tests to both the intervention and control groups. After the laughter yoga sessions are completed, data collection tools will be administered again as post-tests to both groups.

Primary Outcomes

  • geriatric depression scale - short form (eight weeks)
  • Psychological Well-being Scale for the Elderly (YPİOÖ) (eight weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-03
Completion: 2026-06-30
Eligibility
Age: 60 Years – 90 Years
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara University
Contact Information
Study Contact:
Fatma Sena Albayrak
+90 552-366-2976
senaalbayrak2976@gmail.com
Fatma Sena Albayrak, graduate student
+90 552 366 2976
senaalbayrak2976@gmail.com
Ankara University Faculty of Nursing
Interventions
  • Other: Lughter yoga — The study divided the intervention and control groups. Participants in the intervention group will be given laughter yoga. Data collection tools will be administered as pre-tests to both the intervention and control groups. After the laughter yoga sessions are completed, data collection tools will be administered again as post-tests to both groups.
Study Locations (1 sites)
Ankara University Faculty of Nursing, Ankara, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Not having a diagnosis of neurocognitive disorders such as Alzheimer's or dementia. * Not having a diagnosis of mental disorder * Being 65 years and older * Literacy * Not having communication problems that would prevent answering the data collection form. * Volunteering to participate in the research Exclusion Criteria: * Having a diagnosis of neurocognitive disorders such as Alzheimer's or dementia. * Having a diagnosis of mental disorder * Being under 60 years of age * Illiteracy * Having communication problems that prevent one from answering the data collection form. * Not volunteering to participate in the research.
Conditions Mood Disorders, Depressive Disorder, Bip...
Phase Not Applicable
Enrollment 2200
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person. Repeated efforts to find the right treatment contribute to poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one roadblock to progress is the lack of large, standardized studies of mood disorders that are needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the Canadian neuroscience community a standardized way of collecting biomarker data from individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial platform' framework will provide a pool of participants who can be recruited into biomarker-based clinical trials.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Rate of participation in the master trial platform (31st March 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-17
Completion: 2029-03-31
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: St. Joseph's Healthcare Hamilton
Collaborators: Unity Health Toronto, Centre for Addiction and Mental Health, Queen's University, University of Ottawa, University of British Columbia, University of Calgary, McGill University, Nova Scotia Health Authority, University of Michigan, Simon Fraser University, University Health Network, Toronto
Principal Investigators:
  • Benicio N Frey (PRINCIPAL_INVESTIGATOR) - St. Joseph's Healthcare Hamilton
Contact Information
Study Contact:
Saba Khoshroo
905-522-1155
skhoshro@stjoes.ca
Alexandra Du
403-220-6533
mi.du@ucalgary.ca
University of Calgary
Valerie H Taylor, MD, PhD
University of Calgary
Interventions
N/A
Study Locations (9 sites)
University of Calgary, Calgary, Alberta T2N 4Z6 Canada
University of British Columbia, Vancouver, British Columbia V6T 2A1 Canada
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 2E2 Canada
McMaster University, Hamilton, Ontario L8P 3B6 Canada
Queen's University, Kingston, Ontario K7L4X3 Canada
University of Ottawa, Ottawa, Ontario K1Z 7K4 Canada
University Health Network, Toronto, Ontario M5T 2S8 Canada
Centre for Addiction and Mental Health, Toronto, Ontario M6J 1H4 Canada
Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario L1N 5S9 Canada
Eligibility Criteria
Inclusion Criteria Patients: 1. 16 years of age or older. 2. Meet criteria for bipolar or depressive disorders as defined by DSM-5. 3. Fluency in English, sufficient to complete the interviews and self-report questionnaires. Inclusion Criteria Healthy Comparison (HC) Participants: 1. 16 years of age or older. 2. No history of psychiatric disorders (according to DSM-5) or significant unstable medical conditions. 3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.
Conditions Depression, Major Depressive Disorder, B...
Phase PHASE4
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is estimated that more than 350 million people worldwide suffer from depression, with a prevalence rate of 2.1% in China, which is approximately 30 million people. At present, due to the lack of neurobiological markers for screening and diagnosing depression, the identification and diagnosis of MDD are based on the judgment of professional doctors, and the treatment mostly relies on clinical symptoms. In terms of treatment, medication remains the main stream for MDD. Although current methods have certain therapeutic effects, patients still suffer from various side effects and poor cognitive function.In current clinical practice, relying purely on symptomatic diagnosis and treatment is difficult to meet the needs of clinical practice, so there is an urgent need to search for neurobiological markers in depression and develop targeted non-invasive intervention technologies. This study aims to combine advanced brain imaging technology, digital twin-brain models, multi-source information decoding technology, integrated detection and intervention technology. The target is to create two new types of non-invasive BCI systems that can regulate emotions. One is a intervention BCI system for MDD that is suitable for hospital settings with the purpose of precise physical stimulation, and the other one is an ecological BCI system that regulate emotions and intervene with depression which is suitable for both hospital settings and future family environments. This study will collect a comprehensive collection of physiological and biochemical indicators from patients with depression and from healthy control groups, as well as multimodal information such as head surface electroencephalography, MRI, and eye movements under different brain states, to personalize the available BCI information of depression related brain regions, circuits, and networks. The study also tries to explore emotional-interactive games that can intervene with depression and build a game data base that is dedicated to MDD. Other goals include designing and establishing two new types of emotional regulation systems, which are precise external physical stimulation intervention and ecological intervention, constructing a BCI regulation system, and conducting application verification to evaluate the regulation effect.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SSRI — Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
  • Device: rTMS — Patients will be treated targeting either the traditional brain region or new region.
  • Behavioral: Neuro-Feedback — Patients under 18 years old will first be considered this treatment before other methods.
  • Behavioral: Game Regulation — Patients will learn how to play several games that can supposedly regulate or affect negative emotions.

Primary Outcomes

  • EEG power in alpha band between the depression patient group and healthy controls. (2 weeks)
  • EEG power in beta band between the depression patient group and healthy controls. (2 weeks)
  • MRI imaging of DLPFC between the depression patient group and healthy controls. (2 weeks)
  • HbO in fNIRS between the depression patient group and healthy controls. (2 weeks)
  • Hb in fNIRS between the depression patient group and healthy controls. (2 weeks)
  • EEG power in alpha band between the depression patient group and healthy controls. (4 weeks)
  • EEG power in beta band between the depression patient group and healthy controls. (4 weeks)
  • MRI imaging of DLPFC between the depression patient group and healthy controls. (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-07-01
Completion: 2027-07-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Mental Health Center
Collaborators: The Fourth People's Hospital of Chengdu, Shanghai Jiao Tong University School of Medicine, University of Electronic Science and Technology of China, East China Normal University
Principal Investigators:
  • Zhenghui Yi, chief physician (STUDY_CHAIR) - Shanghai Mental Health Center
Contact Information
Study Contact:
Zhenghui Yi, chief physician
18017311007
yizhenghui1971@163.com
Qinyu Lv, chief physician
18616550357
lvqinyu_louis@163.com
Min Zhao, chief physician
34773231
Shanghai Mental Health Center
Interventions
  • Drug: SSRI — Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
  • Device: rTMS — Patients will be treated targeting either the traditional brain region or new region.
  • Behavioral: Neuro-Feedback — Patients under 18 years old will first be considered this treatment before other methods.
  • Behavioral: Game Regulation — Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
Study Locations (1 sites)
Shanghai Mental Health Center, Shanghai, Shanghai Municipality 200030 China
Eligibility Criteria
Inclusion Criteria: * ≥ 12 years old, male or female, right-handed, Han ethnicity * Meets the DSM-5 diagnostic criteria for depression, with HAMD-17 scores greater than 17 and YMRS scores less than 6; * Primary school education or above, able to understand the research content, willing to participate in this study and sign an informed consent form Exclusion Criteria: * Concomitant or previous history of organic brain disease or severe traumatic brain injury, personal or family history of epilepsy; * Severe abnormalities in heart, liver, and kidney function; * Patients with severe physical illnesses; * History of substance dependence or abuse (alcohol, cocaine, drugs, etc.); * Patients with mental disorders caused by organic diseases, drug or alcohol induced mental disorders, and other mental disorders; * Pregnancy or lactation period; * Within six months, physical therapy such as MECT and TMS should be used; * Implants of vegetative nerve stimulation; * Individuals who have implanted electronic or metal instruments (such as pacemakers, defibrillators, stents, orthopedic plates, etc.) and undergo ventriculoperitoneal shunt surgery; * Obvious visual and auditory impairment, unable to cooperate in completing neuropsychological and scale assessments.
Conditions Acoustic Stimulation
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

In this study, the investigators will recruit young adults (ages 18-25 years) with elevated anxiety/depression symptoms and sleep disturbance. Participants will complete two overnights in a sleep lab. During one of the overnights, slow-wave activity will be enhanced by delivering sub-arousal auditory tones during slow-wave sleep using a headband device (Philips SmartSleep or Dreem 2). During the other overnight, tones will not be administered. Cognitive and emotional processes will be evaluated using behavioral task performance, self-report, and functional magnetic resonance imaging (fMRI). After the second overnight, participants will take the headband device home and wear it every night for approximately 2 weeks. For half of the participants, the headband will play tones every night and, for the other half, the headband will not play tones. Participants will then return for a final testing visit in which cognitive and emotional processes and anxiety/depression symptoms will be assessed using behavioral task performance and self-report.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Device: Acoustic Stimulation (STIM) — During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
  • Device: No Acoustic Stimulation (SHAM) — During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
  • Device: Daily acoustic stimulation (STIM2) — During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
  • Device: No daily acoustic stimulation (SHAM2) — During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.

Primary Outcomes

  • Acute change in slow-wave activity (Change between two nights, one night in the Sham condition and one night in the Stim condition, separated by ~1-2 weeks)
  • Slow-wave activity (chronic change) (Assessed daily during the ~2 weeks at home)
  • Change in top-down attention d' (Change between three days; one following a night in the Sham condition, one following a night in the Stim condition, and one following either the Sham2 or Stim2 condition; with ~1-2 weeks between each condition)
  • Change in cognitive flexibility d' (Change between three days; one following a night in the Sham condition, one following a night in the Stim condition, and one following either the Sham2 or Stim2 condition; with ~1-2 weeks between each condition)
  • Change in frontoparietal cognitive control circuit activity (Change between two days, one following a night in the Sham condition and one following a night in the Stim condition, separated by ~1-2 weeks)
  • Change in frontoparietal cognitive control circuit activity (Change between two days, one following a night in the Sham condition and one following a night in the Stim condition, separated by ~1-2 weeks)
  • Change in negative affect (Change between three days; one following a night in the Sham condition, one following a night in the Stim condition, and one following either the Sham2 or Stim2 condition; with ~1-2 weeks between each condition)
  • Change in frontolimbic emotional reactivity circuit activity (Change between two days, one following a night in the Sham condition and one following a night in the Stim condition, separated by ~1-2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-24
Completion: 2027-03
Eligibility
Age: 18 Years – 25 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Michelle Stepan
Collaborators: National Institute of Mental Health (NIMH), Brain & Behavior Research Foundation
Principal Investigators:
  • Michelle E Stepan, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Michelle E Stepan, PhD
7247570761
stepanme@upmc.edu
Michelle E Stepan, PhD
7247570761
stepanme@upmc.edu
University of Pittsburgh
Interventions
  • Device: Acoustic Stimulation (STIM) — During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
  • Device: No Acoustic Stimulation (SHAM) — During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
  • Device: Daily acoustic stimulation (STIM2) — During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
  • Device: No daily acoustic stimulation (SHAM2) — During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
Study Locations (1 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 18-25. Equal numbers of men and women will be included. 2. Normal hearing. 3. Elevated anxiety or depression symptoms. This will be determined using the PROMIS anxiety and PROMIS depression scales. Participants with T-scores ≥ 60 (i.e., ≥ than 1 standard deviation above the mean) on either or both scales will be eligible for participation. 4. Elevated sleep disturbance. This will be determined using the PROMIS sleep disturbance scale. Participants with T-scores ≥ 55 on the PROMIS sleep disturbance scale will be eligible for participation. Exclusion Criteria: 1. Presence of a severe chronic or psychiatric condition including psychosis, bipolar disorder, developmental disorders, or substance use disorder. 2. Current use of psychotropic medications or medications affecting sleep/wake function, such as antidepressants, antipsychotic medications, steroids, and stimulants. Rationale: These medications may affect sleep and cognitive-emotional function. 3. Substance abuse. Rationale: Substance abuse may affect sleep and cognitive-emotional function. 4. Consumption of \&amp;gt; 14 standard alcoholic drinks per week. Rationale: excessive alcohol consumption may interfere with sleep and cognitive-emotional function. 5. Consumption of \&amp;gt; 400mg of caffeine per day, which is roughly equivalent to 3-4 8oz cups of coffee per day. 6. Drug or alcohol use \&amp;lt; 48 hours before the in-lab overnight sessions. Rationale: Recent drug or alcohol use could affect sleep, cognitive-emotional processes, and poses a safety risk. 7. Severe insomnia or sleep apnea symptoms. Insomnia symptoms will be determined using the Insomnia Severity Index. Participants with severe insomnia (i.e., scores \&amp;gt; 21) will not be eligible. Sleep apnea symptoms will be determined using the STOP-Bang questionnaire. Participants with scores ≥ 3 will not be eligible. Rationale: Sleep disturbances which result in low sleep efficiency and frequent awakenings during the night may reduce the effectiveness of acoustic stimulation which targets the deepest stage of sleep (i.e., slow-wave sleep). 8. Extreme bedtimes (\&amp;lt; 10:00pm, \&amp;gt; 1:00am) or wake times (\&amp;lt; 6:00am, \&amp;gt; 10:00am). Rationale: Participants with extreme bed or wake times may have difficulty falling asleep, waking up, or obtaining a sufficient amount of sleep during the in-lab overnight sessions. 9. Short (\&amp;lt;5hrs) or long (\&amp;gt;9hrs) average sleep duration. Rationale: short or long sleepers may have different sleep profiles which could impact the effectiveness of the acoustic stimulation intervention. 10. Uncorrected vision problems. 11. Claustrophobia. Rationale: MRI safety criteria. 12. Metal in body. Rationale: MRI safety criteria. 13. Body Mass Index (BMI) \&amp;gt; 40. Rationale: MRI safety criteria. 14. Pregnancy. Rationale: MRI safety criteria. 15. Left handedness. Rationale: Left-handed people may have different lateralization of neural functioning which could affect the fMRI results. 16. Formal vocal training and Good/Very Good at singing in tune. Rationale: The purpose of the karaoke task is to induce negative self-referential emotions via out-of-tune singing. 17. Does not own a smartphone or tablet. Rationale: Participants may need to download an app (SleepMapper or Alfin) to download their sleep data from the headband device when wearing it at home. 18. Inability or unwillingness to complete study procedures. 19. Hairstyles that prevent access to the scalp (e.g., weave). Rationale: Polysomnography for the in-lab overnights cannot be applied with hairstyles which prevent access to the scalp to apply electrodes.
Conditions Depression, Anxiety
Phase NA
Enrollment 213
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Investigators will evaluate the implementation of an evidence-based, Spanish-language, digital, cognitive-behavioral therapy (dCBT) intervention (SilverCloud) in the Mission community for Latino patients with depression and/or anxiety. 213 participants will be enrolled in a one-armed trial comparing self-guided vs. supported dCBT (SilverCloud).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Behavioral: Supported dCBT — In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
  • Device: Behavioral: Unsupported dCBT — Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.

Primary Outcomes

  • Change in Depression at 8 Weeks (Change from Baseline to Week 8)
  • Change in Anxiety at 8 Weeks (Change from Baseline to Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-18
Completion: 2027-03-01
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 213 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Berkeley
Collaborators: University of California, Irvine, University of California, San Francisco
Contact Information
Study Contact:
Aguilera
650-784-5939
aguila@berkeley.edu
Zuckerberg San Francisco General
Interventions
  • Device: Behavioral: Supported dCBT — In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
  • Device: Behavioral: Unsupported dCBT — Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
Study Locations (1 sites)
Zuckerberg San Francisco General, San Francisco, California 94110 United States
Eligibility Criteria
Inclusion Criteria: 1. PHQ-9 ≥ 10 or GAD-7 ≥ 8 2. Has access to the Internet via smartphone and/or broadband at home, and basic level of technological literacy or willingness to undergo a brief technology use training 3. ≥18 years of age 4. Preference for receiving medical care in Spanish 5. Not in concurrent psychotherapy 6. If currently taking an antidepressant medication, patient must have been on a stable dose for at least 6 weeks, and have no plans to change the dose. We will permit patients on antidepressants to enter the study, as this will increase generalizability. Antidepressant status will be monitored at each assessment to control for those effects, if necessary. Exclusion Criteria: 1. Currently receiving psychotherapy, as this treatment will be offered as a frontline treatment for depression and anxiety, however, patients are allowed to be referred to treatment while participating in this study and initiation of treatment will be monitored and considered in analyses 2. Visual, hearing, voice, or motor impairment or illiteracy that would prevent completion of study procedures 3. Diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, or substance use disorder 4. Severe suicidality (as assessed by expressing suicidal ideation, plan, and intent). Although procedures with back-up plans are in place for patients who develop suicidality (see Human Subjects Section), patients assessed with severe suicidality will be referred to more-intensive treatment resources.
Conditions Chronic Pain, Depressive Disorder, Anxie...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Drug: Ketamine — The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Primary Outcomes

  • Ketamine route of use acceptability. (through study completion, an average of 1 year)
  • Mental Health PHQ9 (through study completion, an average of 1 year)
  • Mental Health GAD7 (through study completion, an average of 1 year)
  • Mental Health PCL5 (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2029-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RIVER Foundation
Principal Investigators:
  • Edward Lesofski, MS (STUDY_DIRECTOR) - RIVER Foundation
Contact Information
Study Contact:
Ed Lesofski
406-465-9504
ed@riverofchange.org
James Taggart, MD
415-713-6654
jrtaggartmd@aol.com
Ed Lesofski, MS
406-465-9504
ed@riverofchange.org
RIVER Telehealth
Interventions
  • Drug: Ketamine — The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
Study Locations (1 sites)
RIVER Telehealth, Helena, Montana 59601 United States
Eligibility Criteria
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy population
Conditions Depression
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: pregnenolone — Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
  • Other: placebo — Placebo pills are identical-appearing capsules containing cellulose

Primary Outcomes

  • Within-person change in score on the Ruminative Responses Scale (Baseline to 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-01
Completion: 2027-12-31
Eligibility
Age: 40 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beth Israel Deaconess Medical Center
Principal Investigators:
  • Katherine Burdick, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Aleta Wiley, MPH
617-975-8706
awiley3@bidmc.harvard.edu
Aleta Wiley
Beth Israel Deaconess Medical Center
Interventions
  • Dietary Supplement: pregnenolone — Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
  • Other: placebo — Placebo pills are identical-appearing capsules containing cellulose
Study Locations (1 sites)
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * Healthy women ages 40 to 60 years in the menopause transition * Depressive symptoms * Psychotropic medications are allowed if the dose is stable prior to screening and throughout the study * Able to read Arabic numerals and perform simple arithmetic * Able to provide written informed consent Exclusion Criteria: * Systemic hormone therapy * Contraindicated medications with pregnenolone * Systemic corticosteroid * Other psychiatric illnesses that are considered to be primary * Current suicidal ideation * Active substance use disorders * Unstable medical conditions * Obstructive sleep apnea or other primary sleep disorders * Abnormal hepatic and renal function * Known allergy to progesterone, exogenous allopregnanolone, or pregnenolone * History of head injury resulting in loss of consciousness \> 20 min * Inability to comply with barrier contraceptive methods * Known intellectual disability * Investigator judgement that study participation constitutes substantial risk given medical or psychiatric condition * Current or recent participation in clinical trial expected to interfere with risk of or interpretation of study data * Inability to comply with study procedures
Conditions Neuropathic Pain, Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

High-frequency repetitive transcranial magnetic stimulation of the primary motor cortex has shown its effect on refractory neuropathic pain, and rTMS of the dorsolateral prefrontal cortex is commonly used for treatment-resistant depression. The treatment for patients suffering from neuropathic pain and depression, concomitantly, still needs to be studied, as there are some specificities in both symptoms and brain functional MRI.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC — Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
  • Device: Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1 — Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.

Primary Outcomes

  • Comparison of pain relief rates between the two stimulation targets (M1 and DLPFC) (2 weeks after the last rTMS session for each arm)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-26
Completion: 2029-03
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Contact Information
Study Contact:
Roland PEYRON, PhD
(0)4 77 12 78 05
roland.peyron@univ-st-etienne.fr
Hélène RAINGARD, CRA
helene.raingard@chu-st-etienne.fr
Roland PEYRON, PhD
(0)4 77 12 78 05
Roland.Peyron@univ-st-etienne.fr
CHU de Saint-Etienne
Interventions
  • Device: Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC — Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
  • Device: Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1 — Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
Study Locations (1 sites)
CHU de Saint-Etienne, Saint-Etienne, 42055 France
Eligibility Criteria
Inclusion Criteria: * Central or peripheral neuropathic pain * Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale * Pain present on a daily or near-daily basis (at least 4 days a week) * Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain * Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study. * Patient with a depressive episode characterized according to DSM V criteria * Indication for motor cortex rTMS by a neurologist * Patient can be followed for the entire duration of the study * Patient having received informed consent to participate in the study, and having co-signed a consent form with the investigator * Member or beneficiary of a social security scheme Exclusion Criteria: * Industrial accident or litigation * Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia) * Drug or psychoactive substance abuse * Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease) * Presence of other pain more severe than that justifying inclusion * Patient unable to understand informed consent * Patient unwilling or unable to stop treatments prohibited during the study * Patient participating in another research protocol involving a drug within the 30 days prior to inclusion * Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard) * Minor patient
Conditions Depressive Disorder, Major, Post Traumat...
Phase PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Ketamine — Intravenous ketamine
  • Drug: Perampanel — Oral perampanel (6 mg)
  • Drug: Placebo — Oral placebo

Primary Outcomes

  • Prefrontal functional connectivity (During ketamine infusion, approximately 2.5 hours)
  • Cerebral metabolic rate of oxygen (CMRO2) (During ketamine infusion, approximately 2.5 hours.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-09-07
Completion: 2032-12
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • John Krystal, MD (PRINCIPAL_INVESTIGATOR) - Yale University Medical School
  • Naomi R Driesen, Ph.D. (PRINCIPAL_INVESTIGATOR) - Yale University Medical School
Contact Information
Study Contact:
Naomi Driesen, Ph.D.
203-508-7765
naomi.driesen@yale.edu
Elizabeth Traester, B.A.
elizabeth.traester@yale.edu
Naomi Drieson, PhD
203-508-7765
naomi.driesen@yale.edu
Yale University
Interventions
  • Drug: Ketamine — Intravenous ketamine
  • Drug: Perampanel — Oral perampanel (6 mg)
  • Drug: Placebo — Oral placebo
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06511 United States
Eligibility Criteria
Inclusion Criteria Substudy #2: * Right-handed as determined by the Edinburgh Handedness Inventory * Current depression as indicated by a score greater than 17 on the full Hamilton Depression Rating Scale * Anti-depressant resistant depressive symptoms, defined by a history of failure of one or more adequate anti-depressant trials * Individuals who have previously received ketamine must have had a positive response. Individuals who report reduced depressive symptoms will be treated as ketamine responders and entered directly into the closed label trial. * Participants will meet DSM-5 Criteria for MDD as determined by the SCID-5 * All participants given ketamine must be engaged in treatment outside of the research protocol. Those who are not currently in treatment may be referred for treatment. * Individuals who are receiving pharmacotherapy for depression must have been receiving the current medication and dose for 4 weeks before randomization. In addition, they should have a plan to continue the current regime of pharmacotherapy for the duration of the trial. * Individuals who are receiving psychotherapy must have been in treatment for four weeks and should have a plan to continue the current regime of psychotherapy for the duration of the trial. * Willing to refrain from caffeine, drug and alcohol use for one week prior to each MRI session * Females will be included if they are not pregnant or breastfeeding and agree to utilize a medically accepted birth control method (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy). Women who are surgically sterile or post-menopausal with cessation of menses for at least one year are not required to use birth control. If a woman should become pregnant during the study, she will be excluded from the trial. * Females will receive ketamine during the follicular phase, i.e., in the first week after the start of the menstrual period, if at all possible. If a prospective participant typically has significant menstrual cramps during this entire follicular phase, she will be studied during another part of her cycle. She will be studied during the same part of her cycle for each scan, if possible. * Able to read and write English * Have at least a 12th grade education level or equivalent Exclusion Criteria Substudy #2: * A score on the Columbia Suicide Severity Rating Scale in the "intent" or "intent with plan" categories or judged by Dr. Krystal or Dr. Driesen to be at serious risk for suicide. * Neurological disorder excluding migraine headaches or more than mild head injury. Individuals with migraines will not complete any ketamine infusion visits within 24 hours of a migraine. More than mild head injury is indicated by the presence of any of the following: * More than half hour unconsciousness after trauma * More than one hour post-traumatic amnesia * Concussive symptoms such as headache, memory problems, nausea/vomiting, irritability, ringing in the ears, dizziness, balance problems, difficulty concentrating or visual disturbances lasting more than one week after injury. * Concussive symptoms as defined above in the first week after injury causing more than one day impairment in typical duties. * Four or more concussive events of less severity than the above will also be grounds for exclusion. These events would include post-trauma symptoms such as the individual being dazed, seeing stars, unconscious for less than one half hour, or post-traumatic amnesia of less than an hour. * Current therapeutic treatment with ketamine * Current treatment with topiramate, memantine, or barbiturates within two weeks of randomization * Daytime use of benzodiazepines * Current treatment with monoamine oxidase inhibitors within 4 weeks of randomization * Treatment with a vagal nerve stimulator, ECT or deep brain stimulation within two weeks of randomization * Psychosis other than psychotic experiences congruent with depressed mood during a period of depression * Insulin-dependent diabetes or non-insulin dependent diabetes that is poorly controlled * Other major medical disorder unless cleared by a study physician * History of violence unless cleared by Dr. Driesen or Dr. Krystal because of extenuating circumstances. For example, an individual whose violent behavior was always coupled with substance abuse and had obtained stable sobriety with no violent incidents or an individual who had received successful pharmacotherapy for impulse control difficulties may be included. * Individual meets criteria for a diagnosis of substance or alcohol use disorder within the three months prior to screening date. Individuals who meet criteria for mild alcohol use disorder within three months prior to screening date may be included in the study at investigator discretion. The diagnosis of mild alcohol use disorder shall be per DSM-5 and involve 2-3 symptoms. The PI's discretion will be based on the symptoms that are reported. The purpose of including individuals with mild alcohol use disorder is to extend recruitment to more individuals who can participate safely in the trial. * A positive on screening urine drug test or, at the study physicians' discretion, on any drug screens given before the scans. * A positive screening breathalyzer test or, at the study physicians' discretion, on any breathalyzer test given before the scans. This applies to all subjects, including those who make criteria for current mild alcohol use disorder. * A 12-lead ECG at screening has clinically significant abnormalities as determined by the physician reading the ECG. * Abnormality on clinical chemistry or hematology examination at the pre-study medical screening. Subjects with laboratory parameters outside the reference range for this age group will only be included if the study physician considers that such findings will not introduce additional risk factors. * History of positive HIV or Hepatitis B * Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the MRI scan. Subjects who have taken OTC medication or herbal supplements may still be entered into the study, if, in the opinions of the Principal/Co-Investigator, the medication received will not interfere with the study procedures or compromise safety. * Known sensitivity to ketamine or heparin * Resting blood pressure lower than 85/55 or higher than 140/90, or resting heart rate lower than 45/min or higher than 100/min, unless cleared by study physician. If a subject meets these blood pressure entrance criteria, but is being treated for high blood pressure, the study team will check with the subject's primary care physician or treatment provider to confirm that the subject is stable and normotensive on their current treatment plan. * History of general intellectual disability * History of claustrophobia * Any clinically significant impairment of color vision or visual acuity after correction available in the scanner * Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a Yale Magnetic Resonance Research Center standard pre-MRI screening questionnaire * Subjects will be advised not to drive or operate heavy machinery for at least 24 hours after completing the infusion. * Donation of blood in excess of 500 mL within 56 days prior to dosing or similar loss of blood due to other causes. * Potential participants may be eliminated at the discretion of Dr. Krystal, Dr. Driesen, or the study physician.